CMOTEC_B: Revenue doubled and losses narrowed, with Animal Care driving growth and US expansion

About this update from Scandinavian Chemotech Ab Class B

Revenue more than doubled year-over-year, driven by Animal Care, with improved operating cash flow and narrowed losses. Strategic focus on the US and R&D advances position the business for continued growth, despite ongoing financing and market risks.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Scandinavian Chemotech Ab Class B